SPAP – A contribution to alleviating hardship cases according to Article 71a-d KVV
Access to medication and reimbursement of so-called individual case assessments (Art. 71 a-d KVV) for chronic and fatal illnesses is unique in Switzerland. Nevertheless, patients repeatedly fall through the cracks and are unable to access life-saving therapies, especially when it comes to modern therapeutic approaches.
In 2023, the SGMO launched the Swiss Patient Access Program (SPAP) with the following objectives
- Avoid/reduce hardship cases in the processing of Art. 71 a-d KVV applications
- Offer a solution for hardship cases with the involvement of medical experts
- Create evidence for the expert decision based on a checklist for standardised assessment
- Estimation of patient benefit based on routinely collected health data
- The findings of SPAP should be incorporated into the OLU tool
Medical oncologists with patients whose application for reimbursement of costs has been rejected twice by the health insurance company can submit an application for oncological drugs from the following partner companies:
- Roche
- AstraZeneca
- iQone
